..since I assume that they've been shorting it for the past few hours. Perhaps another one Monday at some point, particularly if they run it up at the open. I bought some for my wife @ 83, got jumpy and sold at about the same price. Now I'm shorting it in her account to see if I can somehow make it up to her ... just a little.
However, the UBS analyst, Roden, raised his price target to 125 yesterday. His comments, as reported on the SA Market Currents page: "Beating Herceptin in a controlled trial (ISPY-2) changes the way that we think about neratanib's potential from being a late-line player in metastatic breast cancer and mutation subgroups to having the potential to compete with high flyers Perjeta and Kadycla in the larger breast cancer segment."
On the Analyst Rating Network, as excerpted on Market Pulse here, I see news of a Stifel upgrade; however, all I can find in the news is the previously announced Stifel downgrade. Puzzling.
They could say that the drug is also producing strong results in areas other than breast cancer, which would make it one of the more important drugs of the decade.
If we didn't hold right now, we'd be giving the feds - and in my case the State of California - a huge Christmas present in return for one day's uncertainty. As for greed, I assume that you're shorting it here - not a bad idea if you cover before Monday PM - and that this speculation is motivated by ........?
We will see by this time tomorrow.
Up only 3 bucks. Other than the hopeful shorts, no one seems to want to sell this stock. At one point this morning,I noted that the bid was 101.22 and the ask was 101.73. If I were short, gaps like that would be disquieting.
All RAD has to do is make enough money to stay in business. Ultimately, either WAG or CVS will have to buy them.
Given California tax law, it's risky to exercise a stock option and not sell the stock. The difference between the exercised price and fair market value is taxable as ordinary income --- which in the higher brackets is about 13%. Plus, for many, a state AMT tax. Yousell the stock to be sure of havingenough profit in the bank to pay the state (and the Feds) their cut.
Yes. The odd thing was how few of the major funds had stakes in this. Adage was buying up sizable chunks,but Baker Brothers Advisors, probably the premier biotech fund, had only a tiny stake. What reassured me was Auerbach's attitude in the analyst presentations, which bordered on arrogant. He certainly didn't waste any time flattering them. The strength of the rally has been remarkable. Continued good luck to you.
The options tell you that this is not possible (the 20 points, not the puppy). However, if we can break back through 100, we should take out some of the shorts' stops, which could be good for a little run.
No reason for anyone with a modicum of sense to linger here. Have at it, loonies!
My inclination is to add cautiously, looking to double up, with 50% added by yearend,the other 50% in the first two weeks of 2014. The hopeful thing here is the growing numbers of shorts.
Your friends are no indication. Will definitely test 90's again tomorrow. If it moves up, I think it will be walked up slowly. I will continue to add cautiously.